Short Interest in Evotec SE (NASDAQ:EVO) Expands By 42.0%

Evotec SE (NASDAQ:EVO) was the recipient of a large increase in short interest during the month of September. As of September 15th, there was short interest totalling 271,800 shares, an increase of 42.0% from the August 31st total of 191,400 shares. Based on an average trading volume of 83,900 shares, the days-to-cover ratio is currently 3.2 days. Approximately 0.1% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on EVO. Deutsche Bank Aktiengesellschaft lowered shares of Evotec from a “hold” rating to a “sell” rating in a research note on Thursday, August 8th. HC Wainwright decreased their target price on shares of Evotec from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, August 15th. Finally, Morgan Stanley cut shares of Evotec from an “overweight” rating to an “equal weight” rating and decreased their target price for the company from $15.00 to $6.00 in a research note on Monday, July 29th.

Evotec Stock Up 2.3 %

NASDAQ EVO traded up $0.08 during trading hours on Friday, reaching $3.57. The company’s stock had a trading volume of 116,721 shares, compared to its average volume of 107,509. The firm has a fifty day simple moving average of $3.68 and a 200-day simple moving average of $5.02. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42. Evotec has a 52 week low of $2.85 and a 52 week high of $12.00.

Hedge Funds Weigh In On Evotec

Several large investors have recently bought and sold shares of the stock. Novo Holdings A S purchased a new position in Evotec during the 2nd quarter valued at about $71,183,000. Mubadala Investment Co PJSC bought a new position in shares of Evotec during the fourth quarter valued at approximately $53,931,000. Optiver Holding B.V. grew its stake in Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after purchasing an additional 69,936 shares during the period. DCF Advisers LLC grew its stake in shares of Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock worth $552,000 after acquiring an additional 67,156 shares during the last quarter. Finally, Cetera Advisors LLC bought a new position in shares of Evotec during the first quarter valued at $188,000. 5.81% of the stock is currently owned by institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.